We are a VC fund focused on investing in early-stage companies in the healthcare sector: biotechnology, medical devices and eHealth.
Invivo Ventures is managed by Invivo Capital Partners, promoted by Luis Pareras and Albert Ferrer, with the experience gained through the first fund Healthequity. The fund was registered to the Comisión Nacional del Mercado de Valores (CNMV) in March 2019 and has achieved a first closing of 40M €.
We are a team of highly qualified professionals, with the scientific, technical and financial know-how required to analyse and make investments to provide value to the invested company. We also have a network of contacts and key strategic relationships in the health ecosystem.
Our company is financed by the European Investment Fund, the Instituto de Crédito Oficial, the Institut Català de Finances, the Institut Valencià de Finances and other private investors.
We seek projects according to the following criteria:
We set initial investments in the range of 0.5-2M €, and after achieving pre-established milestones we can reach up to 4M €.
State of development
We focus on investing in companies in early stages, mainly in the technology transfer phase. In the case of biotechnology companies, they should have a solid proof of concept in animal models, and in the case of medical devices or digital health companies, a prototype close to the market.
We invest in Spain a significant amount of the funds raised, while a smaller percentage is considered for investments syndicated with other funds in European companies.
We want to diversify risks by investing in companies in different stages and different sub-sectors within the biomedical area, such as biotechnology, medical devices and digital health.
Healthequity is a VC fund focused on investing in early-stage companies in the Healthcare sector. Promoted by the Medical Association of Barcelona and the financial group Riva y Garcia, it was registered with the CNMV and founded in 2012.
The fund finished its first investment period in early 2019.
GlyCardial Diagnostics is a company that aims to develop a "laboratory-based" in vitro diagnosis (IVD) test to detect Apo J-Glyc in blood as a promising biomarker for the early diagnosis of cardiac ischemia and the prediction of patient's evolution after an ischemic event.
Versantis is a pharmaceutical company specialized in the development of products aimed at unmet medical needs in the diagnosis, prevention and treatment of liver diseases.
Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment.
Minoryx is a biotechnology company committed to finding innovative treatments for life threatening rare diseases, currently focused on Inborn Errors of Metabolism.
SANIFIT is a biotechnology company focused on treatments for calcification disorders. Their lead product SNF472 commenced phase I clinical trials in early 2014.
nLife Therapeutics is a biotechnology company leading the discovery and development of oligonucleotides as therapeutic agents for those CNS disorders where unmet medical needs are not covered by traditional treatments.
Arthex Biotech S.L is a biotechnology company dedicated to the development of antisense therapies against miRNAs to treat myotonic dystrophy disease, which is an unmet medical need.
Pulmobiotics aims to develop new biotherapeutic drugs to treat lung infections using synthetic biology tools.
Gyala Therapeutics is a spin off from Hospital Clínic – IDIBAPS (Barcelona) focused on developing new CAR-T therapies for treating hematological malignancies.
Telum Therapeutics provides a Platform to develop Phage-encoded endolysins as bactericidal agents for multi-drug resistant infections. According to WHO, antimicrobial resistance is an increasingly serious threat to global public health.
OneChain Immunotherapeutics is a spin-off Company from Instituto de Investigación contra la Leucemia Josep Carreras and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.
Degree and PhD in Medicine (UB) and specialist in Neurosurgery and Global Executive MBA (IESE).
He founded the Innovation and entrepreneurship program at the Barcelona Medical Association (CoMB), where he has been coaching entrepreneurs as well as founded and directed the Healthcare Investment Forums since 2009.
He has been an entrepreneur himself in the healthcare space and raised capital from investors.
Deeply involved in the innovation ecosystem, he is a member and advisor of many healthcare innovation organizations such as Biocat (Board of Trustees), CIMTI, Barcelona Activa Mentoring Program, Generalitat de Catalunya-CASOST and HEALTHIO, among others.
Author of numerous books in the field of innovation, venture capital and healthcare, such as Innovation and Entrepreneurship in Healthcare, published internationally. In the academic space, he has taught in several business schools about healthcare innovation and venture capital.
He remains as the Director of Healthequity, a venture capital fund focused in early-stage companies in the healthcare sector, where he led the investment strategy and transaction processes of the different portfolio companies. He is also a former member of the Board of Directors of different life-sciences companies including Healthequity's investments: Versantis, n-Life Therapeutics and Minoryx Therapeutics.
He founded the managing company Invivo Capital Partners together with Albert Ferrer.
Graduated in Business Administration and MBA (ESADE), Master CEMS (Community of European Management Schools) in Management (HEC – Hautes Études Commerciales, Paris) and Chartered Financial Analyst (CFA).
He has been involved in the Spanish VC industry for the past 15 years through Grupo Financiero Riva y García with a focus on high-growth, early stage, and technology centered investments. He has been a member of the Board of Directors of various companies such as Wecare-u and Scytl.
Previously, he led the finance department of an internet start-up and worked in the marketing department of multinational corporations.
He has specialised in corporate and asset valuation, transaction structuring and execution, and has experience in different transactions: capital increases, mezzanine loans, company acquisitions, trade sales, asset sales and international transactions.
He remains as the Director of Healthequity, a venture capital fund focused in early-stage companies in the healthcare sector. He led the investment strategy and transaction processes of the different portfolio companies, and has been a member of the Board of Directors of different life-sciences companies and of Healthequity's investments: Sanifit, Peptomyc and GlyCardial Diagnostics.
He founded the managing company Invivo Capital Partners together with Luis Pareras.
Bachelor of Science in Biotechnology (UAB), PhD in Biotechnology (UB) and a Postgraduate course in Innovation Management (UAB).
Her research in gene therapy applications in the cancer field have led to publications in scientific journals and collaborations with biotech companies.
She has been Project Manager in the Knowledge Transfer and Innovation Unit at the Research Institute of the Vall d'Hebron Hospital (VHIR) in Barcelona.
She is an active member in the EIT Health Alumni Network, after her participation in the EIT Health Innovation & Business Creation Summer School (2016) organized by the Trinity College in Dublin and IESE business school.
She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Imagine IF!, FIPSE and CIMTI, among others).
Since January 2018, she works as investment analyst in Healthequity, and since 2019 at Invivo Ventures, the first fund of Invivo Capital Partners.
Bachelor of Science in Biotechnology (UAB), PhD in Genetics (UB) and Master’s Degree in Management of Business Aspects of Science and Technology (UPF Barcelona School of Management).
She has done research in Developmental Genetics and Control of Cell Growth (IRB Barcelona), being the author of several scientific publications.
She has been Project Manager in drug development at the biotech company Advancell, and Portfolio Manager and Business Development at the Knowledge Transfer and Innovation unit at Vall d'Hebron Institute of Research in Barcelona (VHIR).
She also created the working group ASBTEC and Business through the non-profit Association of Biotechnologists of Catalonia (ASBTEC) to foster relations between scientific research and biotech companies.
She usually collaborates with different entities of the health innovation ecosystem as a start-up mentor and evaluator (COMB, EIT Health, Ship2b, Fundació Bosch i Gimpera, among others) and as a teacher in the Project management for pharma development process postgraduate course (UB).
Since May 2016, she has been working as Investment analyst at Healthequity, and since 2019 at Invivo Ventures, the first fund of Invivo Capital Partners.
BSc & MSc Civil and transport Engineering (UPC) and BSc Economics (UB).
He has worked in the financial and operations department of the technologic start-up Exoticca, collaborating in the fundraising of the company, and in n a financial boutique specialized in M&A from the Spanish industrial sector.
Moreover, he has consulting experience in the financial, engineering and market intelligence consulting sectors.
Since April 2019, he works as an Investment analyst in Healthequity and Invivo Ventures, Invivo Capital Partners first fund.
For 18 years she worked at the Barcelona Medical Association. Since 2012, when Healthequity was founded, she has worked as Office Manager and Executive Assistant carrying out administration tasks, client and supplier relations, agenda, conference and travel planning and management, both for the directors and the team, as well as managing events like the Healthcare Investment Forums and the Ready4Growth seminars.
She currently works at Invivo Capital as Executive Assistant, Office Manager and Social Media Manager.
Every crisis brings risks and opportunities to the table… here’s a mind map on how SARS-CoV-2 can impact the activities and value chain of the life sciences VC industry
Most rare diseases still lack approved treatments despite major advances in the knowledge of their molecular basis. Here’s a map of the different therapeutic modalities plus an update on some of the most interesting new developments in each field.
Fund financed by FEDER: